非肌肉浸润性膀胱癌的当前临床试验。
Current clinical trials in non-muscle invasive bladder cancer.
作者信息
Siddiqui Mohammad Rashid, Grant Campbell, Sanford Thomas, Agarwal Piyush K
机构信息
Bladder Cancer Section, Urologic Oncology Branch, National Cancer Institute, NIH, Bathesda, MD.
Department of Urology, George Washington University Medical Center, Washington, D.C.
出版信息
Urol Oncol. 2017 Aug;35(8):516-527. doi: 10.1016/j.urolonc.2017.06.043.
BACKGROUND
The treatment options for non-muscle invasive bladder cancer (NMIBC) remain limited. Bacillus Calmette-Guerin (BCG) was the last major breakthrough in bladder cancer therapy almost 4 decades ago. There have been improvements in the understanding of immune therapies and cancer biology, leading to the development of novel agents. This has led to many clinical trials that are currently underway to find the next generation of therapies for NMIBC.
METHOD
We reviewed clinicaltrials.org and pubmed.gov to find the recently completed and ongoing clinical trials in NIMBC. Included in this review are clinical trials that are currently active and trials that were completed in and after 2014.
RESULT
Many trials with BCG-naive and BCG-unresponsive/recurrent/refractory/failure patients with NMIBC are either currently underway or have been recently completed. A wide variety of novel therapeutic agents are being investigated that range from cytotoxic agents to immunomodulatory agents to targeted molecular therapies. Other approaches include cancer vaccines, gene therapies, and chemoradiation potentiation agents. Novel drug-delivery methods are also being tested.
CONCLUSION
This comprehensive update of current trials provides researchers an overview of the current clinical trial landscape for patients with NMIBC.
背景
非肌肉浸润性膀胱癌（NMIBC）的治疗选择仍然有限。卡介苗（BCG）是近40年前膀胱癌治疗领域的最后一项重大突破。在免疫疗法和癌症生物学的理解方面已有进展，促使新型药物得以开发。这引发了许多正在进行的临床试验，旨在寻找NMIBC的下一代治疗方法。
方法
我们检索了clinicaltrials.org和pubmed.gov，以查找NIMBC中最近完成和正在进行的临床试验。本综述纳入了目前仍在进行的临床试验以及2014年及之后完成的试验。
结果
许多针对初治BCG和BCG无反应/复发/难治/失败的NMIBC患者的试验正在进行或最近已经完成。正在研究各种各样的新型治疗药物，从细胞毒性药物到免疫调节药物，再到靶向分子疗法。其他方法包括癌症疫苗、基因疗法和放化疗增效剂。新型药物递送方法也在进行测试。
结论
本次对当前试验的全面更新为研究人员提供了NMIBC患者当前临床试验情况的概述。
Zotero 插件